> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# China's 2026 dual-list overhaul puts 51 Class 1 drugs into NRDL, cuts prices on high-cost therapies
- URL: https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/
- Published: 2026-11-15T14:17:40.000Z
- Updated: 2026-11-15T14:17:44.000Z
- Description: NHSA Notice No. 29 of 2026 adds 107 drugs (51 Class 1) to basic NRDL and expands the commercial list to 28 from Jan 1, 2027, cutting 60%+ of candidates at expert review and delisting four non-renewed drugs.
- Author: Lin Yi
- Tags: Desk analysis, Market Access, Pipeline, Oncology & ADC, GLP-1 & Metabolic

China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security published the 2026 National Reimbursement Drug List (NRDL) and Commercial Health Insurance Innovative Drug List on November 14, 2026 ([Notice No. 29 of 2026](https://www.nhsa.gov.cn/art/2026/11/14/art%5F104%5F23384.html?ref=chinapharmadesk.com), signed November 13, effective January 1, 2027). The ninth annual revision adds 107 drugs to basic insurance—including a record 51 Category 1 innovative medicines—while removing 34 drugs and expanding the parallel commercial list by 12 additions to 28 products.

For global biopharma executives, the headline expansion masks a much tighter filter and a new pricing escalator. Only 28.8% of drugs passing formal review survived into the basic NRDL after expert panels eliminated over 60% of candidates, even as a new pre-filing (*yushenbao*) route cut approval-to-reimbursement lag to under five months and a formal transfer bridge pulled two 2025 commercial-list products—including [JW Therapeutics’ (HKEX: 02126) CD19 CAR-T relmacabtagene autoleucel](https://chinapharmadesk.com/china-nrdl-relma-cel-cart-payment/)—down into basic-insurance negotiation.

## The expert-review funnel and pre-filing speed

Public briefings by NHSA Medical Services Director Huang Xinyu, reported by [The Economic Observer](http://www.eeo.com.cn/2026/1115/1093452.shtml?ref=chinapharmadesk.com) and [The Paper](https://www.thepaper.cn/newsDetail%5Fforward%5F34484502?ref=chinapharmadesk.com), quantify how selective China’s reimbursement gate has become. Out of 424 out-of-catalogue applications submitted for the 2026 cycle, 371 passed formal eligibility checks (87.5%), but expert voting panels cut the pool to 148 drugs before negotiations yielded 107 final additions (28.8% of formally eligible filings). “Class 1 innovative status is not an automatic pass through expert review,” Huang said, pointing to heightened crowding across ME-TOO targets (translated from Mandarin).

At the same time, NHSA shortened the clock for differentiated first-in-class assets through its first unapproved-drug pre-filing channel (*yushenbao*). Of 49 unapproved generic names pre-filed before June 2026, 37 cleared formal review and 11 won basic-insurance inclusion—led by Sichuan Baili Pharmaceutical’s (SSE: 688506) EGFR x HER3 bispecific antibody-drug conjugate `izalontamab brengitecan` (`iza-bren` / `BL-B01D1`, branded as `Yizekang`). Approved conditionally in China on June 22, 2026 for third-line or later recurrent/metastatic nasopharyngeal carcinoma (NPC) based on Phase III `BL-B01D1-303` data (confirmed ORR 54.6% vs. 27.0% for physician’s-choice chemotherapy; median PFS 8.38 vs. 4.34 months, HR 0.44), `iza-bren` entered the NRDL less than five months after launch.

| Stage / List                  | 2026 Cycle Figures                                         | Key Policy & Commercial Takeaway                                                         |
| ----------------------------- | ---------------------------------------------------------- | ---------------------------------------------------------------------------------------- |
| **Basic NRDL Funnel**         | 424 applied -> 371 formal -> 148 expert -> **107 added**   | 28.8% pass rate from formal check; >60% cut at expert review due to target crowding      |
| **Class 1 & Recent Launches** | **51** Class 1 drugs; 103 of 107 approved within 5 years   | Record Class 1 count, aided by 11 winners from 49 pre-filed (*yushenbao*) assets         |
| **Basic NRDL Total & Exits**  | **3,331 total** (1,935 Western, 1,396 TCM); **34 removed** | Net +78 codes; 4 failed-renewal negotiated drugs get 6-month transition to Jun 30, 2027  |
| **Commercial Insurance List** | **+12 added -> 28 total** (2 transferred to basic NRDL)    | First-year 2025 list reached 1,710 sites, \~30,000 patient-uses, \~RMB 600M ($83M) sales |

## The two-way bridge: from RMB 1.29M self-pay to basic NRDL—and 28 commercial-list heirs

Notice No. 29 operationalizes NHSA’s “commercial insurance first, basic insurance next” staircase. In the 2025 inaugural commercial list, 18 active products achieved coverage across 1,710 hospitals and designated retail pharmacies, generating roughly RMB 600 million (approx. $83.3 million) across nearly 30,000 patient-uses by October 2026\. This cycle, two 2025 commercial-list products—JW Therapeutics’ `relma-cel` (`Carteyva` / `Beinuoda`) and Shandong New Time Pharmaceutical’s `sapropterin`—moved up into basic NRDL. According to [China Business Journal / Securities Times reporting](https://www.xueqiu.com/4136216371/416921137?ref=chinapharmadesk.com), `relma-cel`’s negotiated payment dropped from its RMB 1.29 million (approx. $179,000) list price to below RMB 300,000 (approx. $41,700), aided by in-house lentiviral vector localization—a manufacturing switch JW Therapeutics explicitly tied on November 15 to a concurrent [HK$160.0 million ($20.6 million) share subscription](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1115/2026111500081.pdf?ref=chinapharmadesk.com). Under Notice No. 29, drugs graduating from the commercial list retain commercial-list hospital exemptions (exclusion from self-pay rate metrics and DRG/DIP standard caps) for two agreement cycles (four years).

Meanwhile, 12 new ultra-high-cost assets stepped onto the [2026 Commercial Health Insurance Innovative Drug List](https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=445afaff508d4c77b04b3593011a8841.pdf&ref=chinapharmadesk.com) for January 1, 2027–December 31, 2028:

- **Three domestic CAR-T therapies**: CARsgen Therapeutics’ (HKEX: 02171) `satricabtagene autoleucel` (`satri-cel` / `Kaolimei`), China’s and the world’s first approved solid-tumor CAR-T (CLDN18.2+ 3L+ gastric/GEJ cancer, approved June 2026); Chongqing Precision Biotech’s pediatric CD19 CAR-T `pukiaoleucel` (`Pulidekai`); and Hrain Biotechnology’s `leiniaoleucel` (`Hengkailai`) for 3L+ LBCL.
- **China’s first hemophilia B gene therapy**: Belief BioMed’s AAV vector `BBM-H901` (`dalnacogene ponparvovec` / `Xinjiaoning`), which halved its self-pay sticker price in June 2026 from RMB 2.79 million (approx. $387,500) to RMB 1.39 million (approx. $193,000) before winning its commercial-list slot.
- **Radiopharmaceuticals and global rare-disease biologics**: Novartis’s PSMA radioligand `Pluvicto` (`lutetium Lu 177 vipivotide tetraxetan`), [Grand Pharmaceutical Group’s (HKEX: 00512)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1115/2026111500001.pdf?ref=chinapharmadesk.com) `Yigantai` (Y-90 resin microspheres for unresectable mCRC liver metastases), Sanofi’s `caplacizumab` (`Cablivi`) for iTTP, Biogen’s `tofersen` for SOD1-ALS, AstraZeneca’s `eplontersen` for ATTRv-PN, Kyowa Kirin and Winhealth Pharma’s `mogamulizumab` and `burosumab`, and Yifan Pharmaceutical’s (SZSE: 002019) pediatric `diazoxide` suspension.

Basic-insurance pooling funds are prohibited from paying for commercial-list drugs, but hospitals are shielded from self-pay ratio penalties and DRG/DIP deductions when insured patients receive them—a framework reinforced by [the four-agency hospital formulary Notice No. 18](https://chinapharmadesk.com/china-class1-hospital-formulary-policy/).

## Cross-company ledger: Nov 14–15 NRDL winners, crowded classes, and 4 failed renewals

Company filings across HKEX and Shanghai on November 15 reveal fierce category compression—most visibly in type 2 diabetes (T2D) and breast cancer, where five metabolic entrants and multiple CDK/ADC assets entered simultaneously:

| Company & Ticker                                            | Key 2026 NRDL Additions / Expansions (Effective Jan 1, 2027)                                                                                                                                                                                                   | Strategic & Competitive Coordinate                                                                                                                 |
| ----------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Innovent Biologics** (01801.HK)                           | **7 products**: First-time mazdutide (GCG/GLP-1, T2D), picankibart (IL-23p19, psoriasis, Q12W), ipilimumab N01 (CTLA-4 + sintilimab, MSI-H/dMMR colon neoadjuvant), quizartinib (FLT3-ITD AML); new indications sintilimab, pirtobrutinib; tafolecimab renewed | Brings Innovent’s NRDL portfolio to 17 drugs; mazdutide enters T2D alongside Pfizer’s ecnoglutide & Novo’s IcoSema (obesity remains out-of-pocket) |
| **Jiangsu Hengrui** (600276.SS / 01276.HK)                  | **12 products**: First-time zeprumetostat (EZH2, R/R PTCL), ruzinurad (URAT1, gout), henagliflozin/retagliptin/metformin; new indication trastuzumab rezetecan (HER2+ BC); dalpiciclib (eBC adjuvant) + 7 renewals                                             | Disclosed RMB 6.95B (2025) and RMB 6.86B (9M 2026, approx. $953M) aggregate sales across the 12 listed products                                    |
| **Baili-Bio** (688506.SH)                                   | iza-bren (BL-B01D1, EGFR x HER3 ADC) for 3L+ NPC                                                                                                                                                                                                               | Pre-filed & entered <5 months post-approval; 3 more China NDAs under review (TNBC, HR+/HER2- BC, EGFRm NSCLC)                                      |
| **BeOne Medicines** (06160.HK / 688235.SH)                  | **Win**: BCL2 inhibitor sonrotoclax (both BTKi-treated CLL/SLL & 3L+ R/R MCL). **Exit**: PARP inhibitor **pamiparib failed renewal**                                                                                                                           | Only BCL2 inhibitor in NRDL for MCL; pamiparib delisted alongside 3 other drugs with a 6-month transition to Jun 30, 2027                          |
| **Hansoh Pharma** (03692.HK)                                | aumolertinib (Ameile) + chemo 1L EGFRm NSCLC; inebilizumab (Xinyue) 2 new indications (IgG4-RD, gMG); flumatinib & PEG-loxenatide renewed                                                                                                                      | All approved indications of Hansoh’s marketed innovative drugs are now NRDL-covered                                                                |
| **Shanghai Henlius** (02696.HK)                             | serplulimab (Hansizhuang, PD-1) first Category B entry across all approved Mainland indications; fovinaciclib (Futuoning, CDK4/6) 1L HR+/HER2- BC                                                                                                              | Ends years of self-pay friction on serplulimab in SCLC/NSCLC/ESCC/GC as domestic PD-1 reimbursement prices sit below RMB 30,000/yr                 |
| **RemeGen** (09995.HK / 688331.SS)                          | telitacicept prefilled syringe (IgA nephropathy) + lyophilized powder (Sjogren’s); disitamab vedotin \+ toripalimab 1L UC (all HER2 levels)                                                                                                                    | Consolidates domestic autoimmune and HER2 ADC hospital reach ahead of global Phase III readouts                                                    |
| **PegBio** (02565.HK) & **Sunshine Lake** (06887.HK)        | visepegenatide (Paidakang, once-weekly GLP-1, T2D); olorigliflozin (Dong Ze'an, SGLT2/1, T2D)                                                                                                                                                                  | Enter crowded metabolic tier alongside Innovent’s mazdutide, Novo Nordisk’s IcoSema, and Pfizer’s ecnoglutide                                      |
| **Xuanzhu Bio** (02575.HK) & **Sanofi / Chia Tai Tianqing** | Xuanzhu bireociclib (CDK2/4/6) adds 1L HR+/HER2- BC; Sanofi wins 4 NRDL slots including rovadicitinib (JAK/ROCK, MF, licensed from CTTQ in Mar 2026) + aficamten, fitusiran, plozasiran                                                                        | rovadicitinib completes approval, commercial launch, and NRDL listing inside one calendar year after Sanofi’s $1.53B global pact                   |

At the other end of the ledger, 34 medicines were removed from basic insurance, led by four negotiated drugs that failed renewal: **BeOne’s PARP inhibitor `pamiparib`**, `beraprost sodium` sustained-release tablets, `Xiao'er Niuhuang Qingxin` powder, and `Shenlong Ningxin` capsules. Notice No. 29 grants all four a six-month transition through **June 30, 2027**, during which basic-insurance funds may continue paying at prior standards while provincial authorities guide hospital substitution. Separately, products that had already faced intense domestic generic or class competition—such as narrow-label PARP therapies—illustrate NHSA’s willingness to prune redundant incumbents to fund the RMB 170 billion-plus annual negotiated-drug channel.

## Next evidence triggers

With pricing standards confidentially marked by asterisks in the public list, execution now shifts to three verifiable provincial and hospital milestones established by Notice No. 29:

1. **By December 31, 2026**: Provincial procurement platform listing (*guawang*) across all 31 mainland jurisdictions, where net tender ceiling prices become observable for `iza-bren`, `mazdutide`, `sonrotoclax`, and `relma-cel`.
2. **January 1, 2027**: Formal reimbursement switch for all 107 basic-NRDL additions and 28 commercial-list therapies, alongside the six-month exit countdown ending **June 30, 2027** for `pamiparib` and the three other non-renewed drugs.
3. **By February 28, 2027**: Hospital pharmacy and therapeutics (P&T) committee reviews under the four-agency Notice No. 18 mandate, plus provincial Dual-Channel (*Shuangtongdao*) retail pharmacy designations and DRG/DIP special-case exception logs. For regulatory mechanics behind hospital stocking and DRG exceptions, see our [China pharma glossary](https://chinapharmadesk.com/china-pharma-glossary/).